Search

637 Result(s)
Sort by

BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
biolabs-heidelberg

biolabs-heidelberg

Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Uncommon_Mutations_Database

Uncommon_Mutations_Database

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Rethinking mental health care

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”